CSL collapses 6.1% in one of its sharpest single-session declines
CSL Limited fell 6.09% ($326.56, -$21.16) — one of the steepest single-session declines for Australia's largest biotech in recent quarters. CSL's heavy ASX 200 weighting makes it a significant index drag; at a -6.1% move, the stock alone materially suppresses index performance. The likely driver is either earnings guidance or a development in the plasma therapeutics market — CSL's core Behring business is sensitive to plasma collection volumes and pricing. For super funds with ASX 200 mandates, the CSL selldown is a forced buy/hold/reweight decision that will drive institutional activity through Wednesday's open.
Read at Motley Fool Australia ↗